| Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline AJ Ullmann, JM Aguado, S Arikan-Akdagli, DW Denning, AH Groll, ... Clinical Microbiology and Infection 24, e1-e38, 2018 | 1475 | 2018 |
| Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance P Koehler, M Bassetti, A Chakrabarti, SCA Chen, AL Colombo, M Hoenigl, ... The Lancet Infectious Diseases 21 (6), e149-e162, 2021 | 855 | 2021 |
| Tackling the emerging threat of antifungal resistance to human health MC Fisher, A Alastruey-Izquierdo, J Berman, T Bicanic, EM Bignell, ... Nature reviews microbiology 20 (9), 557-571, 2022 | 719 | 2022 |
| Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents RJM Brüggemann, JWC Alffenaar, NMA Blijlevens, EM Billaud, ... Clinical Infectious Diseases 48 (10), 1441-1458, 2009 | 518 | 2009 |
| Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion PE Verweij, BJA Rijnders, RJM Brüggemann, E Azoulay, M Bassetti, ... Intensive care medicine 46 (8), 1524-1535, 2020 | 370 | 2020 |
| Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome FL van de Veerdonk, MG Netea, M van Deuren, JWM van der Meer, ... Elife 9, e57555, 2020 | 350 | 2020 |
| International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus PE Verweij, M Ananda-Rajah, D Andes, MC Arendrup, RJ Brüggemann, ... Drug Resistance Updates 21, 30-40, 2015 | 335 | 2015 |
| European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia JA Maertens, C Girmenia, RJ Brüggemann, RF Duarte, CC Kibbler, ... Journal of Antimicrobial Chemotherapy 73 (12), 3221-3230, 2018 | 330 | 2018 |
| Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial M Van Den Boogaard, AJC Slooter, RJM Brüggemann, L Schoonhoven, ... Jama 319 (7), 680-690, 2018 | 286 | 2018 |
| Antifungal drugs: what brings the future? R Van Daele, I Spriet, J Wauters, J Maertens, T Mercier, S Van Hecke, ... Medical mycology 57 (Supplement_3), S328-S343, 2019 | 233 | 2019 |
| Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters C Smit, S De Hoogd, RJM Brüggemann, CAJ Knibbe Expert opinion on drug metabolism & toxicology 14 (3), 275-285, 2018 | 219 | 2018 |
| Diagnosing COVID-19-associated pulmonary aspergillosis PE Verweij, JP Gangneux, M Bassetti, RJM Brüggemann, OA Cornely, ... The Lancet Microbe 1 (2), e53-e55, 2020 | 198 | 2020 |
| Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines M Mikulska, D Averbuch, F Tissot, C Cordonnier, M Akova, T Calandra, ... Journal of Infection 76 (1), 20-37, 2018 | 184 | 2018 |
| ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children A Warris, T Lehrnbecher, E Roilides, E Castagnola, RJM Brüggemann, ... Clinical Microbiology and Infection 25 (9), 1096-1113, 2019 | 179 | 2019 |
| Therapeutic drug monitoring of voriconazole RJM Brüggemann, JP Donnelly, RE Aarnoutse, A Warris, NMA Blijlevens, ... Therapeutic drug monitoring 30 (4), 403-411, 2008 | 172* | 2008 |
| Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis L Wong, Z Radić, RJM Brüggemann, N Hosea, HA Berman, P Taylor Biochemistry 39 (19), 5750-5757, 2000 | 164 | 2000 |
| Pharmacokinetics and pharmacodynamics of posaconazole L Chen, EHJ Krekels, PE Verweij, JB Buil, CAJ Knibbe, RJM Brüggemann Drugs 80 (7), 671-695, 2020 | 160 | 2020 |
| Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis PE Verweij, RJM Brüggemann, E Azoulay, M Bassetti, S Blot, JB Buil, ... Intensive care medicine 47 (8), 819-834, 2021 | 150 | 2021 |
| Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B AH Groll, BJA Rijnders, TJ Walsh, J Adler-Moore, RE Lewis, ... Clinical Infectious Diseases 68 (Supplement_4), S260-S274, 2019 | 143 | 2019 |
| The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections T Tängdén, V Ramos Martín, TW Felton, EI Nielsen, S Marchand, ... Intensive care medicine 43, 1021-1032, 2017 | 135 | 2017 |
